NCT03855228

Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in Participants With Seasonal Allergic Rhinitis (C94-145)

Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in the Treatment of Seasonal Allergic Rhinitis (Study No. C94-145)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 704 (actual)
• Sponsor: Organon and Co · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of mometasone furoate nasal spray (MFNS) with the addition of loratadine vs MFNS alone, loratadine alone, or placebo, in the treatment of patients with seasonal allergic rhinitis.

Conditions

• Rhinitis, Allergic

Interventions

Type	Name	Description
DRUG	Mometasone furoate nasal spray (MFNS)	Daily dose of 200 µg of mometasone furoate administered as a nasal spray for 15 days.
DRUG	Loratadine	Daily dose of 10 mg of loratadine administered as an oral tablet for 15 days.
DRUG	Placebo nasal spray	Daily dose of placebo administered as a nasal spray for 15 days.
DRUG	Placebo tablet	Daily dose of placebo administered as an oral tablet for 15 days.

Timeline

• Start date: 1995-03-01
• Primary completion: 1995-08-07
• Completion: 1995-08-07
• First posted: 2019-02-26
• Last updated: 2022-02-09
• Results posted: 2019-07-26